SCHEMBL2117318

SCHEMBL2117318

COc1cc(S(=O)(=O)Nc2cc(-n3cccc3)ccc2C)cnn1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
MAPT P10636 4/20 0.43
ALDH1A1 P00352 3/20 0.43
PKM P14618 2/20 0.43
POLB P06746 1/20 0.43
HSD17B10 Q99714 1/20 0.43
KDM4E B2RXH2 1/20 0.43
BLM P54132 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
P2RX7 Q99572 2/20 0.39
CYP2C9 P11712 3/20 0.38
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KEAP1 Q14145 1/20 0.38
GHSR Q92847 2/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119955 0.84 KMT2A (0.43) MEN1KMT2AMAPTALDH1A1PKM
SCHEMBL2119327 0.84 MEN1 (0.46) MEN1KMT2AMAPTALDH1A1PKM
SCHEMBL2116719 0.78 P2RX7 (0.39) MEN1KMT2AMAPTALDH1A1PKM
SCHEMBL2117300 0.76 MAPT (0.46) MEN1KMT2AMAPTALDH1A1PKM
SCHEMBL2117278 0.75 KMT2A (0.46) MEN1KMT2AMAPTALDH1A1PKM
SCHEMBL2116901 0.75 TRIM24 (0.49) MAPTALDH1A1POLBCYP2C9TSHR
SCHEMBL2119994 0.75 GHSR (0.47) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL2118542 0.75 MEN1 (0.52) MEN1KMT2AMAPTALDH1A1PKM
SCHEMBL2120261 0.75 KMT2A (0.52) MEN1KMT2AMAPTALDH1A1PKM
SCHEMBL2120628 0.75 ALDH1A1 (0.59) MEN1KMT2AMAPTALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 MEN1 3143/4885KMT2A 290/4885MAPT 4747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.